INAB - IN8BIO, INC.
IEX Last Trade
0.247
0 0%
Share volume: 17,300
Last Updated: Fri 27 Dec 2024 07:13:18 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.25
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
6.00%
1 Month
-14.11%
3 Months
-10.99%
6 Months
-71.73%
1 Year
-82.08%
2 Year
-86.02%
Key data
Stock price
$0.25
DAY RANGE
$0.25 - $0.26
52 WEEK RANGE
$0.23 - $1.93
52 WEEK CHANGE
-$81.57
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: William T. Ho
Region: US
Website: in8bio.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: in8bio.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, which is in Phase I clinical trial for glioblastoma and solid tumors. InB-100, an allogeneic product candidate, is in clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.
Recent news